Sutro Biopharma downgraded by Wedbush with a new price target

3/14/25 7:41:51 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Wedbush downgraded Sutro Biopharma from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STRO

Date	Price Target	Rating	Analyst
6/16/2025	$2.00	Neutral → Overweight	Piper Sandler
3/17/2025		Buy → Neutral	H.C. Wainwright
3/14/2025		Mkt Outperform → Mkt Perform	Citizens JMP
3/14/2025	$8.00 → $2.00	Outperform → Neutral	Wedbush
3/14/2025	$11.00 → $1.00	Buy → Underperform	BofA Securities
5/8/2024	$12.00	Buy	BofA Securities
11/9/2023	$12.00	Buy	Deutsche Bank
10/6/2023	$10.00	Outperform	Oppenheimer